Apatinib and gamabufotalin co-loaded lipid/Prussian blue nanoparticles for synergistic therapy to gastric cancer with metastasisOA
Apatinib and gamabufotalin co-loaded lipid/Prussian blue nanoparticles for synergistic therapy to gastric cancer with metastasis
Due to the non-targeted release and low solubility of anti-gastric cancer agent,apatinib(Apa),a first-line drug with long-term usage in a high dosage often induces multi-drug resistance and causes serious side effects.In order to avoid these drawbacks,lipid-film-coated Prussian blue nanoparticles(PB NPs)with hyaluronan(HA)modification was used for Apa loading to improve its solubility and targeting ability.Furthermore,anti-tumor compound of gamabufotalin(CS-6)was selected as a partner of Apa with reducing dosage for combinational gastric therapy.Thus,HA-Apa-Lip@PB-CS-6 NPs were constructed to synchro-nously transport the two drugs into tumor tissue.In vitro assay indicated that HA-Apa-Lip@PB-CS-6 NPs can synergistically inhibit proliferation and invasion/metastasis of BGC-823 cells via downregulating vascular endothelial growth factor receptor(VEGFR)and matrix metalloproteinase-9(MMP-9).In vivo assay demonstrated strongest anti-tumor growth and liver metastasis of HA-Apa-Lip@PB-CS-6 NPs adminis-tration in BGC-823 cells-bearing mice compared with other groups due to the excellent penetration in tumor tissues and outstanding synergistic effects.In summary,we have successfully developed a new nanocomplexes for synchronous Apa/CS-6 delivery and synergistic gastric cancer(GC)therapy.
Binlong Chen;Yanzhong Zhao;Zichang Lin;Jiahao Liang;Jialong Fan;Yanyan Huang;Leye He;Bin Liu
Health Management Center,The Third Xiangya Hospital,Central South University,Changsha,410013,China||Department of Urology,The Third Xiangya Hospital,Central South University,Changsha,410013,ChinaHealth Management Center,The Third Xiangya Hospital,Central South University,Changsha,410013,ChinaDepartment of Laboratory Medicine,The Third Xiangya Hospital,Central South University,Changsha,410013,ChinaCollege of Biology,Hunan University,Changsha,410082,ChinaDepartment of Urology,The Third Xiangya Hospital,Central South University,Changsha,410013,China
ApatinibGamabufotalinLipid/Prussian blue nanoparticlesGastric cancer
《药物分析学报（英文）》 2024 (005)
707-721 / 15
This work was partially supported by Changsha Municipal Nat-ural Science Foundation(Grant No.:kq2014265),the Construction Program of Hunan's innovative Province(CN)-High-tech Industry Science and Technology Innovation Leading Project(Project No.:2020SK2002),the Natural Science Foundation of Hunan Province(Grant No.:2023JJ40130),Postgraduate Scientific Research Innova-tion Project of Hunan Province(Project No.:CX20230317),and the Changsha Platform and Talent Plan(kq2203002).
评论